Natural history of platelet antibody formation against αIIbβ3 in a French cohort of Glanzmann thrombasthenia patients

Haemophilia

Volumn 18, Issue 3, 2012, Pages

  Fiore, Mathieu ^a   Firah, N ^b   Pillois, X ^a   Nurden, P ^a   Heilig, R ^c   Nurden, A T ^a  

^a Ctr Geriatrie Ctr Hosp Univ B   (France)

^b HÔPITAL PELLEGRIN   (France)

^c CENTRE NATIONAL DE SÉQUENÇAGE   (France)

Author keywords

IIb 3; Isoimmunization; Platelet antibody; RFVIIa; Thrombasthenia

Indexed keywords

THROMBOCYTE ANTIBODY;

A2BBETA3 GENE; ADOLESCENT; ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY SCREENING; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; FRANCE; GENE; GENE MUTATION; GLANZMANN DISEASE; HUMAN; ITGA2B GENE; ITGB3 GENE; MALE; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTE AGGREGATION;

ADOLESCENT; ADULT; AGED; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FRANCE; HUMANS; INTEGRIN ALPHA2; INTEGRIN BETA3; ISOANTIBODIES; MALE; MIDDLE AGED; MUTATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBASTHENIA; YOUNG ADULT;

EID: 84860318053     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02744.x     Document Type: Article

References (38)

1. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 1: 10.
2. Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118: 5928-37.
3. Bolton-Maggs PH, Chalmers EA, Collins PW et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 603-33.
4. Di Minno G, Coppola A, Di Minno MN, Poon MC. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues. Thromb Haemost 2009; 102: 1157-64.
5. Poon MC, D'Oiron R, Von Depka M et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096-103.
6. Santoro C, Rago A, Biondo F et al. Prevalence of allo-immunization anti-HLA and anti-integrin alphaIIbbeta3 in Glanzmann Thrombasthenia patients. Haemophilia 2010; 16: 805-12.
7. Martin I, Kriaa F, Proulle V et al. Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies. Br J Haematol 2002; 119: 991-7.
8. Flood VH, Johnson FL, Boshkov LK et al. Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatr Blood Cancer 2005; 45: 971-5.
9. Taaning E, Knudsen FU, Thorsen S, Jonsson V. Immunization against platelet glycoprotein IIb-IIIa in Glanzmann's thrombasthenia. Eur J Haematol 1997; 58: 360-1.
10. Kaplan C. Foetal and neonatal alloimmune thrombocytopaenia. Orphanet J Rare Dis 2006; 1: 39.
11. Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011; 17: e858-69.
12. Bellucci S, Damaj G, Boval B et al. Bone marrow transplantation in severe Glanzmann's thrombasthenia with antiplatelet alloimmunization. Bone Marrow Transplant 2000; 25: 327-30.
13. Conte R, Cirillo D, Ricci F, Tassi C, Tazzari PL. Platelet transfusion in a patient affected by Glanzmann's thrombasthenia with antibodies against GPIIb-IIIa. Haematologica 1997; 82: 73-4.
14. Levy-Toledano S, Tobelem G, Legrand C et al. Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function. Blood 1978; 51: 1065-71.
15. Gruel Y, Brojer E, Nugent DJ, Kunicki TJ. Further characterization of the thrombasthenia-related idiotype OG. Antiidiotype defines a novel epitope(s) shared by fibrinogen B beta chain, vitronectin, and von Willebrand factor and required for binding to beta 3. J Exp Med 1994; 180: 2259-67.
16. Jallu V, Diaz-Ricart M, Ordinas A, Pico M, Vezon G, Nurden AT. Two human antibodies reacting with different epitopes on integrin beta 3 of platelets and endothelial cells. Eur J Biochem 1994; 222: 743-51.
17. Hay CR, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
18. Nurden AT, Kunicki T, Nurden P et al. Mutation analysis for a patient with Glanzmann thrombasthenia who produced a landmark isoantibody to the alphaIIbbeta3 integrin. J Thromb Haemost 2010; 8: 1866-8.
19. Bierling P, Fromont P, Elbez A, Duedari N, Kieffer N. Early immunization against platelet glycoprotein IIIa in a newborn Glanzmann type I patient. Vox Sang 1988; 55: 109-13.
20. Schlegel N, Gayet O, Morel-Kopp MC et al. The molecular genetic basis of Glanzmann's thrombasthenia in a gypsy population in France: identification of a new mutation on the alpha IIb gene. Blood 1995; 86: 977-82.
21. de la Salle C, Schwartz A, Baas MJ, Lanza F, Cazenave JP. Detection by PCR and HphI restriction analysis of a splice site mutation at the 5′ end of intron 15 of the platelet GPIIb (alpha IIb integrin) gene responsible for Glanzmann's thrombasthenia type I in Gypsies originating from the Strasbourg area. Thromb Haemost 1995; 74: 990-1.
22. Fiore M, Pillois X, Nurden P, Nurden AT, Austerlitz F. Founder effect and estimation of the age of the French Gypsy mutation associated with Glanzmann thrombasthenia in Manouche families. Eur J Hum Genet 2011; 19: 981-7.
23. Fiore M, Nurden AT, Vinciguerra C, Nurden P, Pillois X. Rapid diagnosis of the French gypsy mutation in Glanzmann thrombasthenia using high-resolution melting analysis. Thromb Haemost 2010; 104: 1076-7.
24. Clofent-Sanchez G, Lucas S, Laroche-Traineau J et al. Autoantibodies and anti-mouse antibodies in thrombocytopenic patients as assessed by different MAIPA assays. Br J Haematol 1996; 95: 153-60.
25. Chong BH, Du XP, Berndt MC, Horn S, Chesterman CN. Characterization of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood 1991; 77: 2190-9.
26. Basch RS, Kouri YH, Karpatkin S. Expression of CD4 by human megakaryocytes. Proc Natl Acad Sci U S A 1990; 87: 8085-9.
27. Thiele J, von Ammers E, Wagner S, Degel C, Fisher R. Megakaryocytopoiesis in idiopathic thrombocytopenic purpura: a morphometric and immunohistochemical study on bone marrow biopsies with special emphasis on precursor cells. Hematol Pathol 1991; 5: 75-82.
28. Nurden P, Poujol C, Winckler J et al. Immunolocalization of P2Y1 and TPalpha receptors in platelets showed a major pool associated with the membranes of alpha-granules and the open canalicular system. Blood 2003; 101: 1400-8.
29. Leticee N, Kaplan C, Lemery D. Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb-IIIa: Is there a foetal risk? Eur J Obstet Gynecol Reprod Biol 2005; 121: 139-42.
30. Kashiwagi H, Kiyomizu K, Kamae T et al. Molecular analysis of a patient with type I Glanzmann thrombasthenia and clinical impact of the presence of anti-alphaIIbbeta3 alloantibodies. Int J Hematol 2011; 93: 106-11.
31. Milet-Marsal S, Breillat C, Peyruchaud O et al. Analysis of the amino acid requirement for a normal alphaIIbbeta3 maturation at alphaIIbGlu324 commonly mutated in Glanzmann thrombasthenia. Thromb Haemost 2002; 88: 655-62.
32. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
33. Kavakli K, Gringeri A, Bader R, Nisli G, Polat A, Aydinok Y. Inhibitor development and substitution therapy in a developing country: Turkey. Haemophilia 1998; 4: 104-8.
34. Scharrer I, Neutzling O, Schwaab R, Oldenburg J, Ehrlich H. Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy. Ann Hematol 1998; 76(Suppl. 1): A1-6.
35. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-3.
36. Nurden AT. Glanzmann thrombasthenia: the need for epidemiological studies. J Thromb Haemost 2009; 7: 1875-7.
37. Nurden A, Combrie R, Nurden P. Detection of transfused platelets in a patient with Glanzmann thrombasthenia. Thromb Haemost 2002; 87: 543-4.
38. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 2006; 12(Suppl. 6): 15-22.